A Study to Assess Alpha DaRT224 for the Treatment of Men With Non-metastatic Locally Recurrent Prostate Cancer

Inclusion Criteria

• •Histologically confirmed locally recurrent prostate adenocarcinoma cancer confined to at least 1 hemi-gland with concordant pathology and imaging findings within 6 months prior to consenting
• •Targetable lesion by either PSMA PET-CT according to PERCIST v1.0 or by multiparametric MRI according RECIST v1.1
• •Patient being considered for focal salvage brachytherapy
• •Lesion size ≤ 3 cm in the longest diameter
• •Target lesion technically amenable for full tumor coverage with the Alpha DaRT seeds
• •Pre-salvage PSA level (rPSA) below \<10 ng/ml
• •Age ≥ 18 years old
• •ECOG Performance Status Scale ≤ 2
• •Subjects' life expectancy is more than 6 months
• •Negative metastatic workup on at least standard imaging (CT CAP and bone scan). Other metastatic screening studies allowed in lieu of standard imaging including multiparametric MRI prostate/whole body, PSMA PET, F18 PET or Axumin PET within 3 months before visit 0
• •Platelet count ≥100,000/mm3
• •Subjects are willing and able to sign an informed consent form.